Sign in
  1. Home
  2. Companies
  3. PetMed Express
  4. Financial Ratios
PetMed Express logo
PetMed Express PETS
$ 1.96 -1.76%
report update icon

Quarterly report 2026-Q3
added 06-02-2026

PetMed Express Financial Ratios 2026-2009 | PETS

Brief overview of PetMed Express's valuation multiples

This overview follows the five latest available observations from 2019 through 2023.

The current valuation set is P/E 61.93x (median 30.68x), EV/EBITDA 11.18x (median 11.18x), P/S 0.25x (median 0.31x). Ratios sit near their own comparison base, with an average deviation of 0% from five-year medians.

At the current P/E, inverse earnings yield is 1.6%, a useful bridge between price and business earnings.

End-period return metrics are ROE -197.9%, ROA -70.6%, ROCE -2%. Returns below zero mean resources are not producing positive profit. Recovery in operating results is the main reference point.

The cash cycle lengthened by 290.9 days to 4.3 days. Operations require more funding.

Overall picture

PetMed Express's valuation and business quality look relatively balanced, with no pronounced distortion in either direction.

Annual Financial Ratios PetMed Express

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009

P/E

 -0.8 -8.4 -11.3 61.9 16.9 132.5 30.7 11.8 18.3 19.6 17.9 18.2 14.5 14.5 16.7 16.3 16.8 -

P/S

 0.2 0.2 0.3 5.0 5.5 8.4 2.8 1.6 2.5 1.9 1.6 1.4 1.1 1.1 1.2 1.5 - -

EPS

 -2.7 -0.3 -0.4 0.2 0.9 1.2 1.3 1.8 1.8 1.2 1.0 0.9 0.9 0.9 0.8 0.9 1.1 -

EV (Enterprise Value)

 75.4 M 61.6 M 102 M 272 M 262 M 434 M 715 M 366 M 622 M 428 M 338 M 289 M 250 M 240 M 241 M 299 M 384 M -30.1 M

EBITDA per Share

 -2.36 0.27 -0.05 0.47 1.34 1.64 1.66 2.37 2.67 1.92 1.65 1.5 1.46 1.41 1.33 1.53 1.79 -

EV/EBITDA

 -1.5 11.2 -92.3 28.3 9.7 10.7 20.7 7.2 11.1 10.5 10.0 9.4 8.3 8.2 8.4 8.4 9.5 -

PEG

 0.0 0.05 0.25 -2.47 -3.9 50.5 -1.02 14.97 0.33 1.27 1.04 -5.28 3.0 2.29 -1.29 -0.85 - -

P/B

 1.5 0.6 0.9 2.9 2.6 3.6 6.1 3.3 5.9 5.0 4.4 4.2 3.7 3.9 3.4 3.5 - -

P/CF

 -1.6 11.2 19.5 11.4 17.1 12.6 21.7 10.0 18.6 12.8 399.0 10.2 19.4 19.7 14.1 11.5 - -

ROE %

 -197.95 -7.37 -7.72 4.67 15.16 3.06 19.88 28.02 32.22 25.51 24.72 23.14 25.59 26.81 20.52 21.52 26.85 -

ROA %

 -70.56 -4.22 -4.39 3.07 10.42 2.04 16.64 24.44 27.65 21.11 22.78 21.07 22.93 23.46 18.29 19.64 - -

ROCE %

 -202.74 -1.80 -8.44 5.50 19.68 24.44 23.65 34.00 44.66 39.68 38.93 38.88 40.15 42.08 31.86 33.93 41.86 -

Current Ratio

 1.6 2.3 2.3 2.9 3.2 4.1 5.3 6.8 5.8 4.5 9.5 10.8 9.2 7.8 9.3 10.0 - -

DSO

 4.3 4.5 3.3 10.5 14.3 19.4 4.9 3.3 3.1 2.6 2.7 3.1 2.8 2.3 2.4 3.1 - -

DIO

 - 51.8 145.4 - - - 32.2 41.5 48.4 43.5 59.0 59.8 83.7 76.5 60.5 62.1 - -

DPO

 - 70.1 317.0 217.4 300.9 49.3 35.4 31.6 31.7 32.7 11.5 12.3 13.5 15.6 15.3 15.9 - -

Operating Cycle

 4.3 56.3 148.8 10.5 14.3 19.4 37.1 44.7 51.5 46.1 61.6 62.8 86.5 78.8 62.9 65.3 - -

Cash Conversion Cycle

 4.3 -13.8 -168.2 -206.9 -286.6 -29.9 1.7 13.2 19.8 13.4 50.1 50.5 73.0 63.2 47.7 49.3 - -

All numbers in USD currency

Quarterly Financial Ratios PetMed Express

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

 -0.5 -0.41 -1.65 -0.5 -0.03 0.11 - -0.03 0.11 0.18 - -0.1 0.04 -0.06 - -0.01 0.13 0.26 - 0.21 0.75 0.53 - 0.38 0.38 0.42 0.39 0.34 0.34 0.33 0.26 0.38 0.38 0.53 - 0.45 0.43 0.46 - 0.24 0.81 0.57 - 0.24 0.75 0.51 - 0.24 0.62 0.39 - 0.23 0.68 0.45 - 0.23 0.63 0.4 - 0.19 0.61 0.41 -

EBITDA per Share

 -0.38 -0.29 -1.53 -0.38 0.06 0.11 - 0.06 0.11 0.3 - -0.06 0.13 -0.02 - 0.01 0.19 0.4 0.34 0.29 1.03 0.74 0.27 0.49 0.49 0.55 0.5 0.43 0.43 0.45 0.33 0.49 0.49 0.67 0.68 0.59 0.63 0.74 0.7 0.4 0.42 0.4 0.51 387 406 371 449 0.39 0.41 0.23 0.39 0.36 0.39 0.35 0.36 0.38 0.4 0.63 0.31 0.3 0.29 0.3 0.34

ROE %

 -150.45 -118.98 -96.79 -31.27 3.35 8.10 5.69 3.66 5.03 2.43 -1.58 0.29 6.58 5.95 5.95 8.97 19.78 17.91 25.59 24.46 26.91 21.86 20.52 23.36 23.24 23.11 22.17 20.16 20.67 21.22 24.50 29.34 31.72 34.12 34.80 35.94 33.09 30.18 26.49 24.48 25.13 25.82 25.92 25.63 26.11 26.61 24.62 24.07 24.15 24.23 26.73 27.07 27.84 26.80 30.18 27.62 25.13 24.35 19.25 19.37 4.94 4.56 4.99

ROA %

 -63.58 -52.07 -41.99 -11.38 2.21 5.16 3.56 2.39 3.33 1.61 -0.85 0.68 5.29 4.84 4.84 7.37 16.92 15.40 21.62 20.54 22.56 17.92 16.87 19.51 19.53 19.44 18.88 17.34 17.72 18.28 20.72 24.82 26.54 28.29 28.63 29.30 27.56 25.54 23.07 22.15 22.73 23.26 23.17 22.82 23.31 23.81 22.17 21.57 21.61 21.40 23.32 23.47 23.90 23.19 26.54 24.38 22.32 21.63 17.13 17.34 4.43 3.95 4.55

ROCE %

 -149.58 -118.09 -98.06 -32.31 0.21 5.37 4.80 1.72 2.96 1.72 -2.97 -0.83 7.21 6.44 6.44 10.09 23.94 21.80 31.42 30.30 33.32 26.95 25.21 28.63 28.16 27.67 26.55 23.87 24.75 25.68 29.57 37.09 40.44 44.93 48.83 52.17 50.30 47.26 41.66 38.72 39.58 40.49 40.65 40.20 41.20 42.25 39.09 38.20 38.03 37.85 41.79 42.34 43.71 42.21 47.49 43.42 39.45 38.18 30.08 30.23 7.73 7.06 7.80

Current Ratio

 1.6 1.8 1.9 1.6 3.0 2.9 2.3 3.0 2.9 2.6 2.3 2.4 3.5 - 2.9 3.1 5.4 - 5.2 6.1 8.9 5.3 4.1 5.9 7.0 5.5 6.1 6.8 7.3 6.8 7.8 6.5 8.1 5.3 7.1 5.3 6.1 4.7 5.8 11.8 11.3 7.4 12.7 11.5 9.7 6.0 11.2 12.7 10.5 6.2 9.6 11.8 7.3 5.3 8.0 8.2 9.7 8.0 9.2 10.3 9.7 7.5 11.4

DSO

 4.0 3.7 2.8 4.3 3.3 3.0 - 3.4 3.0 3.7 - 2.9 1.4 1.0 - 2.7 1.1 0.6 2.2 2.4 0.9 1.5 2.5 2.8 3.4 4.0 3.6 2.7 2.4 2.7 2.7 2.3 2.7 2.5 2.7 2.8 2.8 2.2 2.4 2.5 2.6 2.4 - - - - - - - - - - - - - - - - - - - - -

DIO

 34.4 47.3 37.9 - 29.8 31.6 - 31.7 14.1 26.1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DPO

 50.2 55.9 50.0 - 33.4 43.7 - 35.5 44.7 56.1 - 61.8 22.7 20.6 - 50.5 23.3 12.9 - 35.1 11.0 27.7 - 37.4 36.5 35.4 23.9 34.4 33.3 29.2 28.7 38.8 39.8 36.0 - 27.3 28.1 27.5 - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Cycle

 - - - 4.3 - - - 35.1 17.1 3.7 - 2.9 - - - 2.7 1.1 0.6 2.2 2.4 0.9 1.5 2.5 2.8 3.4 4.0 3.6 2.7 2.4 2.7 2.7 2.3 2.7 2.5 2.7 2.8 2.8 2.2 2.4 2.5 2.6 2.4 - - - - - - - - - - - - - - - - - - - - -

Cash Conversion Cycle

 - - - 4.3 - - - -0.4 -27.6 -52.4 - -58.9 - - - -47.8 -22.2 -12.3 2.2 -32.8 -10.1 -26.2 2.5 -34.6 -33.1 -31.4 -20.2 -31.7 -31.0 -26.5 -26.0 -36.4 -37.1 -33.6 2.7 -24.4 -25.3 -25.3 2.4 2.5 2.6 2.4 - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company PetMed Express, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Pharmaceutical retailers industry

Issuer Price % 24h Market Cap Country
BOQI International Medical BOQI International Medical
BIMI
 		- 6.33 % $ 5.86 M chinaChina
Аптеки 36.6 Аптеки 36.6
APTK
 		- - - russiaRussia
China Jo-Jo Drugstores, Inc. China Jo-Jo Drugstores, Inc.
CJJD
 		- -5.59 % $ 49.9 M chinaChina
Trxade Group Trxade Group
MEDS
 		- 4.55 % $ 5.8 M usaUSA
Rite Aid Corporation Rite Aid Corporation
RAD
 		- - $ 35.5 M usaUSA
Walgreens Boots Alliance Walgreens Boots Alliance
WBA
 		- - $ 10.3 B usaUSA
LifeMD LifeMD
LFMD
 		- - $ 169 M usaUSA
Greenlane Holdings Greenlane Holdings
GNLN
 		$ 2.01 -3.37 % $ 15.1 M usaUSA
111 111
YI
 		$ 3.75 -1.45 % $ 653 M chinaChina